+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 21 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects vision. This study aims to learn if a medicine called tiespectus also known as MK-8748 or EYE201 can treat NVAMD as well as the standard treatment called aflibercept. The trial is a pivotal Phase 23 study that compares these treatments in people newly diagnosed with NVAMD. Participants are randomly assigned to one of three groups one group receives a low dose of tiespectus, another receives a high dose of tiespectus, and the third group receives aflibercept. Those in the tiespectus groups get three initial injections every 4 weeks, then continue injections every 8 weeks until week 48, followed by treatments at intervals based on their individual response up to week 92. The aflibercept group receives three initial injections followed by injections every 8 weeks until week 92. During the study, participants are regularly assessed for changes in their best-corrected visual acuity using ETDRS letters from baseline to one year. Other evaluations include eye imaging to measure retinal thickness and monitoring for any adverse events up to approximately 96 weeks. The study lasts over one year with ongoing visits to track treatment response and safety.

Age: 50Years +All GendersPhase 2Phase 3
71 locations
C

Actively Recruiting

Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.

Age: 18Years +All GendersPhase 3
301 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.

Age: 18Years +All GendersPhase 3
333 locations
S

Actively Recruiting

Researchers are studying ASTX030, a combination of azacitidine and cedazuridine, alone or with venetoclax in people with myeloid neoplasms including myelodysplastic syndromes MDS, chronic myelomonocytic leukemia CMML, and acute myeloid leukemia AML. This multi-phase study includes phases 1 through 3 for monotherapy and phases 1 and 2 for combination therapy, aiming to evaluate the safety, pharmacokinetics, and effectiveness of these treatments over approximately 8 years. Participants receive various treatments depending on the study phase and arm. Treatments include oral doses of azacitidine, cedazuridine, ASTX030, subcutaneous azacitidine, and venetoclax in different sequences and cycles, typically lasting 28 days each. Some phases involve dose escalation and expansion stages, while others compare oral and subcutaneous forms or combine ASTX030 with venetoclax. Participants in certain arms may cross over to other treatments later in the study. During the study, participants undergo regular assessments including blood tests to measure drug levels, DNA methylation, and response rates such as complete remission. Researchers track adverse events, survival outcomes, transfusion independence, and pharmacokinetics up to 36 months or longer depending on the phase. Safety monitoring includes up to 24 months for some arms. The study involves scheduled visits for dosing and evaluations, with ongoing data collection to understand treatment effects and safety.

Age: 18Years +All GendersPhase 2Phase 3
73 locations
R

Actively Recruiting

Researchers are gathering real-world data from patients with Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase Ph-CML-CP who are treated with tyrosine kinase inhibitors TKIs approved for first or second line therapy. This registry study aims to collect evidence on the tolerability, safety, effectiveness, and patient-reported outcomes over a prospective follow-up period of 5 years to understand long-term treatment results in routine healthcare settings. Participants will be those receiving TKI treatments including asciminib, bosutinib, dasatinib, imatinib, or nilotinib as prescribed in standard medical care, either as initial therapy or after one prior TKI therapy. The study includes patients who began these treatments on or after specified dates and those continuing asciminib after participating in an interventional trial. There is no treatment allocation instead, patients are observed based on their current prescribed TKI therapy. During the 5-year follow-up, participants treatment continuation and discontinuation due to adverse events will be monitored, along with the occurrence of adverse events, treatment switches, molecular and hematological responses, survival outcomes, and patient-reported measures of health, symptoms, and medication adherence. Data will be collected from electronic medical records and claims data with patient consent, ensuring ongoing safety and effectiveness observations in real-world care up to 5 years.

Age: 18Years - 100YearsAll Genders
17 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of targeted therapies and immunotherapy, either alone or in combination, for patients with metastatic colorectal cancer mCRC whose tumors test positive for specific biomarkers. This open-label, Phase 11b study enrolls participants into different treatment groups based on their biomarker test results to explore personalized treatment approaches. Participants receive various combinations of study drugs, including oral medications like inavolisib and divarasib and intravenous infusions such as cetuximab, bevacizumab, atezolizumab, tiragolumab, SY-5609, FOLFOX, and FOLFIRI chemotherapy. Treatment cycles vary from 21 to 28 days depending on the assigned treatment arm, with dosing schedules including daily oral medications and infusions given weekly, every two weeks, or every three weeks. Some treatment arms are closed or not recruiting, while others remain active. Throughout the study, participants undergo regular assessments including tumor imaging to measure response, blood tests, and biomarker sampling. Researchers monitor outcomes such as objective response rate, disease control, duration of response, and adverse events over approximately 84 months. Participants overall health and tumor status are closely followed to evaluate treatment effects and safety during and after therapy.

Age: 18Years +All GendersPhase 1
84 locations
P

Actively Recruiting

This research aims to compare overall survival in men with chemotherapy-naefve metastatic castration-resistant prostate cancer. The study evaluates the combination of xaluritamig and abiraterone against the investigators choice of treatments, which include abiraterone, docetaxel, or cabazitaxel. The trial is a phase 3, open-label, randomized study sponsored by Amgen. Participants will be randomly assigned to receive either xaluritamig administered intravenously combined with oral abiraterone acetate, or the investigators choice of one of the following treatments daily oral abiraterone acetate, or intravenous docetaxel or cabazitaxel given every three weeks. Treatments continue with regular monitoring throughout the study period, which lasts up to approximately 51 months for outcome assessments. Participants will undergo various assessments including imaging scans such as CT, MRI, or bone scans to confirm metastatic disease and monitor progression. Researchers will also evaluate pain levels, quality of life, prostate-specific antigen PSA responses, and adverse events throughout the study. Follow-up evaluations will continue for up to 51 months to measure survival and other health outcomes, with safety monitoring conducted throughout the participation period.

Age: 18Years +MALEPhase 3
159 locations
R

Actively Recruiting

Researchers are studying adults with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma that cannot be surgically removed or has spread to other parts of the body. This trial aims to compare the levels of drug exposure following treatment with tislelizumab given as a subcutaneous injection versus an intravenous infusion as first-line therapy. The study includes approximately 351 participants and is sponsored by BeOne Medicines. Participants are randomly assigned to one of two groups one group receives tislelizumab 300 mg as a subcutaneous injection on Day 1 of each 21-day cycle, followed by chemotherapy chosen individually the other group receives tislelizumab 200 mg as an intravenous infusion on Day 1 of each 21-day cycle, also followed by individualized chemotherapy. Chemotherapy drugs may include cisplatin, leucovorin, 5-fluorouracil, oxaliplatin, or capecitabine. The study is divided into a screening period, a treatment period, and a follow-up period. Throughout the study, participants will be monitored for drug levels, tumor response, survival, and adverse events for up to two years. Assessments include measuring the steady state trough concentration and area under the concentration-time curve of tislelizumab, as well as evaluating tumor response rates and disease control. Safety and antibody responses will also be tracked. Participants will undergo regular visits to collect medical data and ensure adherence to the treatment plan during the study period.

Age: 18Years +All GendersPhase 3
95 locations
R

Actively Recruiting

Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.

Age: 18Years +All GendersPhase 2Phase 3
413 locations
O

Actively Recruiting

Researchers are evaluating the safety and effectiveness of BGB-43395 combined with letrozole compared to a choice of approved cyclin-dependent kinase 46 inhibitors abemaciclib, palbociclib, or ribociclib combined with letrozole in adults with advanced or metastatic hormone receptor positive HR and human epidermal growth factor receptor 2 negative HER2- breast cancer. The study focuses on patients who have not previously received systemic treatment for advanced or metastatic disease. This phase 3 trial aims to provide insight into treatment options for this patient group. Participants are randomly assigned to one of two groups one receiving BGB-43395 plus letrozole, and the other receiving an investigators choice of CDK46 inhibitor abemaciclib, palbociclib, or ribociclib plus letrozole. All medications are taken orally. The study compares these treatment combinations over a period lasting up to approximately 4 years for primary outcomes, with longer follow-up for secondary outcomes. During the trial, participants will be regularly monitored for disease progression, response to treatment, overall survival, and safety through various assessments. These include evaluations of progression-free survival by independent review, overall response rate, duration of response, clinical benefit rate, and adverse events. Quality of life measures and other clinical outcomes are also tracked. Participant involvement may last up to 11 years to capture long-term effects and safety.

Age: 18Years +All GendersPhase 3
241 locations

1-10 of 21

1